A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

NCT03717415 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

70

Enrollment

INDUSTRY

Sponsor class

Stopped Development program terminated.

Conditions

Locally Advanced or Metastatic Solid Tumor

Interventions

DRUG: Rebastinib
DRUG: Carboplatin

Sponsor

Deciphera Pharmaceuticals, LLC